Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27915349 | 0.81 | SLC7A5 (0.52) | SLC7A5SLC1A3SLC1A2SLC1A1ALDH1A1 | |
| SCHEMBL4420550 | 0.81 | SLC7A5 (0.52) | SLC7A5SLC1A3SLC1A2SLC1A1ALDH1A1 | |
| SCHEMBL4426649 | 0.81 | SLC7A5 (0.52) | SLC7A5SLC1A3SLC1A2SLC1A1ALDH1A1 | |
| SCHEMBL4423815 | 0.81 | SLC7A5 (0.52) | SLC7A5SLC1A3SLC1A2SLC1A1ALDH1A1 | |
| SCHEMBL16753714 | 0.81 | SLC7A5 (0.52) | SLC7A5SLC1A3SLC1A2SLC1A1ALDH1A1 | |
| SCHEMBL4419903 | 0.81 | SLC7A5 (0.52) | SLC7A5SLC1A3SLC1A2SLC1A1ALDH1A1 | |
| SCHEMBL189158 | 0.81 | SLC7A5 (0.52) | SLC7A5SLC1A3SLC1A2SLC1A1ALDH1A1 | |
| SCHEMBL189157 | 0.81 | SLC7A5 (0.52) | SLC7A5SLC1A3SLC1A2SLC1A1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL15533962 | 0.79 | SLC7A5 (0.50) | SLC7A5SLC1A3SLC1A2SLC1A1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL28009300 | 0.79 | SLC7A5 (0.50) | SLC7A5SLC1A3SLC1A2SLC1A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040091541-A1 | Solid matrix therapeutic compositions | UNGER EVAN C (US) | 2004-05-13 | — | — | US | disclosed |
| EP-0769969-B1 | GAS-FILLED MICROSPHERES WITH FLUORINE-CONTAINING SHELLS | MOLECULAR BIOSYSTEMS INC (US) | 2002-09-18 | — | — | EP | disclosed |
| EP-0983060-A4 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | IMARX PHARMACEUTICAL CORP (US) | 2002-04-24 | — | — | EP | disclosed |
| US-20020039594-A1 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | IMARX THERAPEUTICS, INC. | 2002-04-04 | — | — | US | disclosed |
| US-20010018072-A1 | Solid matrix therapeutic compositions | IMARX THERAPEUTICS, INC. | 2001-08-30 | — | — | US | disclosed |
| EP-0983060-A1 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | IMARX PHARMACEUTICAL CORP. (US) | 2000-03-08 | — | — | EP | disclosed |
| EP-0769969-A4 | GAS-FILLED MICROSPHERES WITH FLUORINE-CONTAINING SHELLS | MOLECULAR BIOSYSTEMS INC (US) | 1999-12-29 | — | — | EP | disclosed |
| WO-1998051282-A1 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | IMARX PHARMACEUTICAL CORP. (US) | 1998-11-19 | — | — | WO | disclosed |
| EP-0769969-A1 | GAS-FILLED MICROSPHERES WITH FLUORINE-CONTAINING SHELLS | MOLECULAR BIOSYSTEMS, INC. (US) | 1997-05-02 | — | — | EP | disclosed |
| US-5562893-A | USED IN ULTRASONIC IMAGING | MOLECULAR BIOSYSTEMS, INC. (US) | 1996-10-08 | — | — | US | disclosed |
| WO-1996004018-A1 | GAS-FILLED MICROSPHERES WITH FLUORINE-CONTAINING SHELLS | MOLECULAR BIOSYSTEMS, INC. (US) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040091541-A1 | Solid matrix therapeutic compositions | MMP7, MMP1, MMP17 | SLC7A5 4372/4885SLC1A3 4452/4885SLC1A2 3750/4885 |
| US-20020039594-A1 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | EXOSC9, EXOSC5, EXOSC4 | SLC7A5 1602/4885SLC1A3 2954/4885SLC1A2 2693/4885 |
| US-20010018072-A1 | Solid matrix therapeutic compositions | MMP7, MMP1, MMP17 | SLC7A5 4372/4885SLC1A3 4452/4885SLC1A2 3750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.